🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Samuel Murray

Novartis (Switzerland)

ORCID: 0000-0003-0074-6462

Also affiliated with Novartis (China)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial”.

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Cancer(2020)10.1002/cncr.33148

N/A

1.2DataRank · unranked

38 citations

Yasser Ged, Chung‐Han Lee, Andrea Knežević, Ana M. Molina, Ying‐Bei Chen +13 more

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0053

N/A

1.2DataRank · unranked

33 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

(2023)10.1158/1541-7786.c.6545243

N/A

0.165DataRank · unranked

2 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.323

N/A

0DataRank · unranked

5 citations

Kyrollis Attalla, Sujata Patil, Samuel Murray, Ying‐Bei Chen, Ritesh R. Kotecha +5 more